GSK Announces $800 Million Investment in Largest U.S. Manufacturing Facility Expansion

Recently, it was reported that GlaxoSmithKline (GSK) announced the largest investment in building a factory in the United States to date — an investment of up to 800 million US dollars. This will equip GSK's plant located in Marietta, Lancaster County, Pennsylvania, with state-of-the-art facilities specifically for drug and vaccine production. The former will produce products based on Multi-Antigenic Peptide System (MAPS) technology, while the latter will manufacture drugs for clinical trials. Additionally, the scale and capacity of the plant will be doubled, creating over 200 new jobs. Since 2017, GSK has invested nearly 1.3 billion US dollars in manufacturing within the United States.

Pennsylvania Governor Josh Shapiro launched a long-term economic strategy in early 2024 aimed at creating jobs and promoting growth in industries such as life sciences, agriculture, energy, and robotics. He confirmed that the Pennsylvania Department of Community and Economic Development (DCED) will support this expansion through a $21 million funding program, marking the largest economic development project in the history of Lancaster County, Pennsylvania. GSK is also expected to apply for additional tax credits under Pennsylvania's Manufacturing Assistance Program. Currently, one in four Americans receives vaccines from the Marietta facility.

According to GSK, the construction plan for the new facility is set to begin by the end of 2024. The completion of API-related facilities is expected by the end of 2027, with the remaining pharmaceutical facilities becoming operational by the end of 2028. Additionally, the plant's new facilities include a clear net-zero emissions pathway, integrating solar panels, cogeneration, and emerging energy recovery technologies, aiming to reduce carbon emissions by 80% by 2030. GSK also claims it will implement the latest technologies to streamline workflows, including establishing AI-driven processes.

Just about a month ago, following the expiration of the contract to produce antibiotic drugs for Sandoz, GSK announced the closure of a 75-year-old manufacturing plant located in the UK. At the same time, GSK stated that the decision to close the plant was not sudden; over the past few years, the company has been dismantling underutilized facilities while streamlining its operations. The expansion of its U.S. plant reflects GSK's efforts to strengthen its own business and also addresses the issue of capacity self-building that MNCs have faced in recent years.

The rapid growth in sales of core products and the expected increase in potential varieties are key factors driving GSK's production expansion.

On July 31, 2024, GSK announced its Q2 financial results for 2024. According to the Q2 earnings report, GSK achieved a total revenue of £7.9 billion (approximately RMB 72.7 billion). Revenue from the vaccines business reached £2 billion (approximately RMB 18.4 billion), representing a 1% year-over-year increase (including COVID-19 solutions); specialty medicines business revenue was £3 billion (approximately RMB 27.6 billion), marking a 22% year-over-year growth; general medicines business revenue amounted to £2.9 billion (approximately RMB 26.6 billion), showing a 12% year-over-year rise. Overall, all three business segments achieved growth.

In the vaccine sector, the highly anticipated RSV vaccine Arexvy generated total sales of 244 million pounds (approximately 311 million US dollars) in the first half of the year, with 182 million pounds in the first quarter and sales dropping to 62 million pounds in the second quarter. Compared to last year's impressive sales performance of 1.238 billion pounds (approximately 1.545 billion US dollars) within just nine months of its launch, the total sales of Arexvy in the first half of this year showed a significant decline.

GSK stated that Arexvy still holds a significant share (about two-thirds) in the retail vaccine market. However, due to seasonal variations in RSV prevalence, overall demand is declining, which is expected. In late June 2024, the U.S. CDC's Advisory Committee on Immunization Practices (ACIP) voted to approve new routine vaccination recommendations for respiratory syncytial virus (RSV) vaccines: the eligible age for RSV vaccination has been adjusted from over 60 years old to over 75 years old. The U.S. CDC also emphasized that only individuals aged 60 to 74 who are at high risk of severe respiratory syncytial pneumonia should receive the RSV vaccine. In other words, the critical population aged over 60 is still not recommended for vaccination, causing the once heated RSV vaccine enthusiasm to cool down significantly.

The road to R&D for RSV vaccines and drugs has always been rugged, with initial results emerging only after 60 years of technological efforts. The world's first RSV vaccine was launched in May 2023, produced by GSK. Subsequently, RSV vaccines from Pfizer and Moderna also came to market, with Pfizer’s vaccine expanding the indications to include pregnant women.

It is worth mentioning another major vaccine variety, the shingles vaccine Shingrix, which achieved sales of 1.777 billion pounds (approximately 2.262 billion US dollars) in the first half of the year, representing a year-on-year increase of 7%. This vaccine is the second-generation recombinant shingles vaccine developed by GSK, and it generated over 1 billion US dollars (approximately 7.1 billion RMB) in revenue for GSK in its first year on the market.

Among them, the performance in the Chinese market is particularly outstanding. With the aggravation of China's aging society and the improvement of public health awareness, Shingrix is rapidly gaining market share in China. Herpes zoster is a type of clustered vesicular disease that often occurs on the skin of elderly people, those with weakened immune function, and individuals with chronic diseases, caused by the reactivation of the varicella-zoster virus latent in neurons. Approximately one-third of the general population will develop herpes zoster in their lifetime, but about half of those aged 85 and above will suffer from it. According to clinical research data previously disclosed by GSK, Shingrix has shown 100% protective efficacy in adults aged 50 and above in China, with protection lasting over 10 years.

GSK signed an "Exclusive Distribution and Co-Promotion Agreement" with ZF Bio, a domestic vaccine company, in October 2023. The agreed procurement period for the products under the agreement is three years, from 2024 to 2026. According to ZF Bio's semi-annual report in 2024, in the first half of 2024, the issuance volume of GSK's recombinant shingles vaccine exceeded 1.6 million doses, achieving coverage of more than 20,000 terminal usage units across China.

In terms of clinical research, GSK has explored more possibilities for Shingrix. At the end of July, GSK announced a statistically significant association between its recombinant zoster vaccine Shingrix and a reduced risk of dementia compared to the live attenuated zoster vaccine Zostavax and the pneumococcal polysaccharide vaccine Pneumovax 23. In other words, adults aged 50 and above who received Shingrix had a lower risk of developing Alzheimer's disease compared to those who received the other two vaccines.

In addition, meningitis vaccines are also an important part of GSK's vaccine business. Both Bexsero and Menveo have shown impressive growth, maintaining double-digit increases with revenues of £449 million (+12%) and £164 million (+35%), respectively. GSK continues to make strides in the meningitis field, with another combination meningitis vaccine, MenABCWY, having its marketing application accepted by the FDA. The PDUFA date is set for February 14, 2025.

Over the past two decades, the professional division of labor in the global pharmaceutical industry chain has become increasingly prominent, with pharmaceutical companies showing a major trend of outsourcing their R&D and manufacturing operations to other specialized companies. However, times are changing, and potential shifts may reverse this trend. Facing intensified market competition and constantly evolving regulatory policies, cash-rich multinational corporations (MNCs) are enhancing their own production capacity and optimizing global resource allocation to strengthen the stable production of key products in the global supply.

Since the beginning of this year, multinational pharmaceutical companies have shown a positive trend in investing in factory construction and expanding production capacity. Several multinational pharmaceutical companies, including AstraZeneca, Novo Nordisk, AbbVie, and Daiichi Sankyo, have successively announced measures to enhance their own production capacities. These methods are not limited to investing in the construction of new factories, acquiring CDMO enterprises, and expanding existing production bases.

Compared with GSK, a company born in the UK, which is expanding its factory scale in the US, American-originated MNCs are more willing to invest heavily in building factories.

At the start of October 2024, Johnson & Johnson and Gilead both announced significant investments in building new facilities to expand their production capacity. On October 1, Johnson & Johnson announced an investment of over $2 billion to construct a state-of-the-art biologics manufacturing plant in Wilson, North Carolina. The new facility will increase the production of the company’s innovative biologics portfolio and pipeline to support Johnson & Johnson's broader initiative of advancing more than 70 new therapies and product expansion filings and launches by the end of this decade.

On October 2, 2024, Eli Lilly announced an investment of $4.5 billion to establish the Lilly Medicine Foundry in Indiana. This new advanced manufacturing and drug development center will enable Eli Lilly to research innovative methods of drug production while expanding the scale of clinical trial drug manufacturing.

It is reported that the pharmaceutical foundry is the first of its kind to combine research and manufacturing in one location. The plant is scheduled to open by the end of 2027, bringing Eli Lilly's total capital commitment in the U.S. to over $23 billion since 2020. Once fully operational, the facility is expected to create 400 high-skilled full-time jobs, including positions for engineers, scientists, operations staff, and laboratory technicians.

Earlier, in May 2024, Eli Lilly announced an additional investment of $5.3 billion to enhance the production capacity of active pharmaceutical ingredients for its latest diabetes and obesity drugs. This milestone marks the largest single investment in active pharmaceutical ingredient production in U.S. history.

AstraZeneca, another UK-based MNC like GSK, has benefited from continuous breakthroughs in the fields of heart failure and chronic kidney disease. To avoid the awkward situation of "one injection hard to come by" and "a billion-dollar market constrained by downstream production capacity," AstraZeneca invested over 2 billion US dollars in production expansion in the first quarter of 2024, demonstrating full efforts to catch up with international peers.

More notably, at the same time GSK announced its factory expansion, AstraZeneca also revealed it is considering relocating its manufacturing facilities from the UK to the US to secure more financial subsidies. As market competition and regional policies evolve rapidly, multinational corporations (MNCs), as leading pharmaceutical enterprises, are flexibly adjusting their strategies according to the new logic of the global industrial chain. This allows them to adapt to the ever-changing market environment while enhancing their global competitiveness by maintaining control over their production capacity.